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Purpose of the study
The purpose of the study was to determine if regular audit
of management of HIV-positive pregnant patients resulted
in improved practice.
Methods
Over a 3-year period from 1 July 2005 to 30 June 2008,
there were 50 deliveries of pregnant mothers who were
HIV-positive and looked after by a joint team from the
Brownlee Centre and Princess Royal Maternity, Glasgow.
Each year an audit meeting reviewed all the pregnancies
with a view to improving the care pathway. The audit
focused on two areas which were measurable and had the
potential to change practice. Changes to practice were re-
audited in subsequent years.
Summary of results
Fifteen pregnancies and 10 deliveries were audited in the
period 1 July 2005 to 30 June 2006, and two specific areas
were identified. First, following a pre-term delivery at 24
weeks gestation, it was recognised that antiretroviral treat-
ment for prevention of mother-to-child transmission
(PMTCT) should be initiated sooner than around 26
weeks. Secondly, therapeutic drug monitoring (TDM)
should be performed in patients on protease inhibitors
(PIs) early in the third trimester to ensure adequate levels.
In 2005–06 the mean gestation for starting antiretroviral
treatment for PMTCT was 26 weeks; in 2006–07 it was 24
weeks; and in 2007–08 it was 22 weeks with one patient
who presented late starting at 38 weeks. TDM was per-
formed in the 3rd trimester on 0 (0%) patients in 2005–
06, in six (50%) patients in 2006–07 and in 19 (95%)
patients on PIs in 2007–08. Twenty-one (84%) had levels
greater than estimated minimum trough concentration
(EMTC), two (8%) had borderline levels equal to EMTC,
and two (8%) had undetectable levels. As a result, two
(8%) with borderline levels had their doses increased
(one lopinavir and one saquinavir) and both had unde-
tectable viral loads at the time of delivery. Suspected non-
adherence was confirmed in the other two patients who
had undetectable PI levels.
Conclusion
Annual audit of all pregnant patients was beneficial in
highlighting areas where improvements could be made to
the care pathway. Antiretroviral treatment for PMTCT is
now initiated at an earlier gestation to ensure undetecta-
ble viral load in case of pre-term labour. TDM has enabled
doses of PIs to be increased if necessary to ensure viral
load is undetectable at delivery. It has also confirmed sus-
pected non-adherence with medication enabling other
action to be taken prior to delivery to reduce risk of MTCT.
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